NZ630721A - Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use - Google Patents

Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Info

Publication number
NZ630721A
NZ630721A NZ630721A NZ63072113A NZ630721A NZ 630721 A NZ630721 A NZ 630721A NZ 630721 A NZ630721 A NZ 630721A NZ 63072113 A NZ63072113 A NZ 63072113A NZ 630721 A NZ630721 A NZ 630721A
Authority
NZ
New Zealand
Prior art keywords
pyrazolo
pyrimidine
compositions
methods
based compounds
Prior art date
Application number
NZ630721A
Other languages
English (en)
Inventor
Kenneth Gordon Carson
Giovanni Cianchetta
Yingzhi Bi
Michael Alan Green
Godwin Kumi
Alan Main
Yulian Zhang
Glenn Gregory Zipp
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NZ630721A publication Critical patent/NZ630721A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ630721A 2012-03-09 2013-03-05 Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use NZ630721A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
NZ630721A true NZ630721A (en) 2016-12-23

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630721A NZ630721A (en) 2012-03-09 2013-03-05 Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Country Status (25)

Country Link
US (3) US8946415B2 (OSRAM)
EP (1) EP2834243B1 (OSRAM)
JP (1) JP6418950B2 (OSRAM)
KR (1) KR101965025B1 (OSRAM)
CN (1) CN104302649B (OSRAM)
AR (1) AR090292A1 (OSRAM)
AU (1) AU2013230128B2 (OSRAM)
BR (1) BR112014022000A8 (OSRAM)
CA (1) CA2866143C (OSRAM)
DK (1) DK2834243T3 (OSRAM)
ES (1) ES2676224T3 (OSRAM)
HU (1) HUE038786T2 (OSRAM)
IL (1) IL234486A (OSRAM)
IN (1) IN2014DN07384A (OSRAM)
MX (2) MX345830B (OSRAM)
NZ (1) NZ630721A (OSRAM)
PL (1) PL2834243T3 (OSRAM)
PT (1) PT2834243T (OSRAM)
RU (1) RU2014140735A (OSRAM)
SG (1) SG11201405561RA (OSRAM)
TR (1) TR201808280T4 (OSRAM)
TW (1) TW201341386A (OSRAM)
UY (1) UY34668A (OSRAM)
WO (1) WO2013134228A1 (OSRAM)
ZA (1) ZA201406149B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013230119B2 (en) 2012-03-09 2017-02-23 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2014130258A1 (en) 2013-02-22 2014-08-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2936079C (en) 2014-01-24 2022-07-19 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
US9932320B2 (en) * 2014-01-31 2018-04-03 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
EP3200797A1 (en) * 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
EP3233863B1 (en) * 2014-12-15 2024-04-10 CMG Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
EP3317285B1 (en) 2015-07-02 2021-01-27 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RS65593B1 (sr) 2015-07-06 2024-06-28 Turning Point Therapeutics Inc Polimorf diaril makrocikla
EP3325488B1 (en) 2015-07-21 2020-06-24 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
ES2765738T3 (es) * 2015-11-02 2020-06-10 Janssen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
KR20190034225A (ko) 2016-07-28 2019-04-01 티피 테라퓨틱스, 인크. 거대환 키나제 억제제
CA3038916A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
BR112019008404A2 (pt) 2016-11-02 2019-09-17 Janssen Pharmaceutica Nv derivados de [1,2,4]triazolo[1,5-a]pirimidina como inibidores da pde2
JP7018944B2 (ja) 2016-11-02 2022-02-14 ヤンセン ファーマシューティカ エヌ.ベー. PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン化合物
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
SI3658148T1 (sl) 2017-07-28 2024-10-30 Turning Point Therapeutics, Inc. Makrociklične spojine in njihova uporaba
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7321183B2 (ja) * 2017-12-15 2023-08-04 ピラミッド バイオサイエンシズ インコーポレイテッド がんを治療するためのtrkキナーゼ阻害物質としての、5-(2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-3-(1h-ピラゾール-1-イル)ピラゾロ[1,5-a]ピリミジン誘導体及び関連する化合物
AU2018392332B2 (en) 2017-12-19 2023-08-03 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating disease
EP3730492A4 (en) 2017-12-22 2021-08-11 Shenzhen TargetRx, Inc. COMPOUND PYRAZOLO [1,5-A] PYRIMIDINE SUBSTITUTE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE
EP3744723B1 (en) 2018-01-23 2023-10-18 Shenzhen TargetRx, Inc. Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
AU2019360941B2 (en) * 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CA3175970A1 (en) 2020-04-21 2021-10-28 Suma GOPINATHAN Aak1 inhibitors for use in treating viral infections
US11666575B2 (en) 2020-04-21 2023-06-06 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing
TW202525819A (zh) * 2023-09-08 2025-07-01 加拿大商薩泰洛斯生物科學公司 Ap2相關激酶1抑制劑及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
BRPI0912668A2 (pt) * 2008-05-13 2016-01-26 Irm Llc composto e composições como inibidores de quinase
PT3372605T (pt) * 2008-10-22 2021-12-09 Array Biopharma Inc Compostos de pirazolo[1,5-a]pirimidina substituídos como inibidores de quinase trk
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011029027A1 (en) 2009-09-03 2011-03-10 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
US8946237B2 (en) 2010-01-14 2015-02-03 Merck Sharp & Dohme Corp. Pyrazolo[1,5-A]pyrimidines as mark inhibitors
US9416132B2 (en) * 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
AU2013230119B2 (en) 2012-03-09 2017-02-23 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
JP2015513557A (ja) * 2012-03-09 2015-05-14 レクシコン ファーマシューティカルズ インコーポレイテッド 疼痛の治療に対するアダプター関連キナーゼ1の阻害
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
ES2676224T3 (es) 2018-07-17
RU2014140735A (ru) 2016-04-27
CA2866143C (en) 2020-08-04
BR112014022000A8 (pt) 2021-06-15
KR20140138864A (ko) 2014-12-04
DK2834243T3 (en) 2018-07-23
JP6418950B2 (ja) 2018-11-07
PL2834243T3 (pl) 2018-09-28
US20130253194A1 (en) 2013-09-26
MX381849B (es) 2025-03-13
AU2013230128B2 (en) 2017-08-17
ZA201406149B (en) 2016-06-29
MX345830B (es) 2017-02-17
KR101965025B1 (ko) 2019-04-02
IN2014DN07384A (OSRAM) 2015-04-24
CN104302649B (zh) 2017-06-23
AU2013230128A1 (en) 2014-09-25
US20150183792A1 (en) 2015-07-02
US9403832B2 (en) 2016-08-02
PT2834243T (pt) 2018-08-01
EP2834243B1 (en) 2018-04-25
AR090292A1 (es) 2014-11-05
UY34668A (es) 2013-10-31
US20170129896A1 (en) 2017-05-11
HUE038786T2 (hu) 2018-11-28
JP2015509535A (ja) 2015-03-30
CA2866143A1 (en) 2013-09-12
IL234486A (en) 2016-10-31
TR201808280T4 (tr) 2018-07-23
WO2013134228A1 (en) 2013-09-12
BR112014022000A2 (pt) 2017-06-20
EP2834243A1 (en) 2015-02-11
US8946415B2 (en) 2015-02-03
SG11201405561RA (en) 2014-10-30
MX2014010589A (es) 2014-09-18
CN104302649A (zh) 2015-01-21
TW201341386A (zh) 2013-10-16
HK1201257A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
NZ600430A (en) Spiro-oxindole mdm2 antagonists
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
NZ609957A (en) Heterocyclic compounds and uses thereof
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
EA201290244A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2012030944A3 (en) Quinoline and isoquinoline derivatives for use as jak modulators
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
NZ702513A (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY CPA GLOBAL

Effective date: 20200123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY CPA GLOBAL

Effective date: 20210121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY CPA GLOBAL

Effective date: 20220121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY CPA GLOBAL

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250116